Faget Comments on FDA Proposal to Streamline Premarket Review Submissions
19 November 2018
MobiHealthNews
Special Counsel Kyle Faget was quoted in a MobiHealthNews article, “Proposed framework lessens FDA’s regulatory requirements for prescription drugs companion apps,” about an FDA proposal that would classify most software released by pharmaceutical companies as “promotional labeling” not requiring premarket review.
Faget welcomed the proposed framework, but warned that any confusion regarding appropriate software classification could hamper the end goal of increased digital adoption.
“Sponsors wishing to enter this space will face several decision-points, including determining if the software application is a device subject to regulatory approval and whether the output of such software is FDA-required labeling or promotional labeling,” she said. “Confusion on any or all of these points may mean sponsors must avail themselves of FDA’s advisory comment process, which very well could have the contradictory effect of deterring software application innovation and use.”
Faget welcomed the proposed framework, but warned that any confusion regarding appropriate software classification could hamper the end goal of increased digital adoption.
“Sponsors wishing to enter this space will face several decision-points, including determining if the software application is a device subject to regulatory approval and whether the output of such software is FDA-required labeling or promotional labeling,” she said. “Confusion on any or all of these points may mean sponsors must avail themselves of FDA’s advisory comment process, which very well could have the contradictory effect of deterring software application innovation and use.”
People
Related News
14 February 2025
In the News
Brian Wheeler Joins Podcast to Discuss Legal Journey
Foley & Lardner LLP partner Brian Wheeler joined the Hsu Untied podcast to discuss his legal career.
14 February 2025
In the News
Pavan Agarwal Featured in Leadership Q&A – 'Reflecting our firm’s core values drives me to do my best'
Foley & Lardner LLP partner Pavan Agarwal is featured by Law.com for his career journey, legal practice, and leadership in the article, “How I Made Practice Group Chair: ‘Keep Listening and Keep Learning,’ Says Pavan Agarwal of Foley & Lardner.”
14 February 2025
In the News
Judith Waltz on Trump Administration Deregulation Order, Impact on CMS
Foley & Lardner LLP partner Judith Waltz commented on the Trump administration's executive order requiring federal agencies cut ten regulations for each newly created one in the Modern Healthcare article, "CMS may evade Trump's sweeping deregulation order."